Drug That Prevents Lung Issues in Premature Babies Also Lowers Costs

by Ramya Rachamanti on  March 14, 2019 at 6:58 PM Clinical Trials News
RSS Email Print This Page Comment bookmark
Font : A-A+

New study done by the researchers at Columbia University Vagelos College of Physicians and Surgeons proves that a drug given to few pregnant women to prevent severe respiratory ailments in preterm newborns reduces healthcare costs.
Drug That Prevents Lung Issues in Premature Babies Also Lowers Costs
Drug That Prevents Lung Issues in Premature Babies Also Lowers Costs

Drug previously shown effective in reducing breathing ailments in preemies

Approximately 7 percent of babies in the U.S. are born in the late preterm period between 34 and 36 weeks of gestation and are more likely to experience severe respiratory problems than fullterm babies.

Based on the results of a clinical trial, published in 2016 in the New England Journal of Medicine, most women at risk for preterm delivery are now given a corticosteroid drug -- to speed a baby's lung development -- that reduces the risk of serious respiratory problems in late preterm babies.

"Doctors have widely adopted this preventive strategy for mothers at risk of giving birth prematurely," says Cynthia Gyamfi-Bannerman, MD, MSc, Ellen Jacobson Levine and Eugene Jacobson Professor of Obstetrics & Gynecology at Columbia University Vagelos College of Physicians and Surgeons and an obstetrician and maternal-fetal medicine specialist at NewYork-Presbyterian/Columbia University Irving Medical Center, who led the clinical trial. "But we didn't really know if it was cost-effective."

Drug saves money spent on breathing problems in newborns

In the new study, Gyamfi-Bannerman and colleagues tallied the healthcare costs of the 1,426 mother-infant pairs in the previous clinical trial who had received at least one injection of the drug, betamethasone, and 1,395 pairs from the same study who did not get the drug.

Costs were estimated for the drug, respiratory treatments for the newborns, and maternal care, including office visits and hospitalizations within the first 72 hours of birth.

The analysis revealed that pairs who received betamethasone had average costs of $4,681 -- significantly lower than the $5,379 spent on the pairs who did not get the treatment. Previous studies to determine the cost-effectiveness of this strategy had mixed results, though they did not look at the same outcomes as those in the clinical trial.

"It's possible to have an intervention that is highly effective but costly in the end. But based on our analysis, we discovered that corticosteroid therapy for mothers at high risk of late preterm delivery is both highly effective and saves money," says Gyamfi-Bannerman.

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Patent Ductus Arteriosus Signature Drug Toxicity Pneumoconiosis Drugs Banned in India Silicosis Top 10 Alarming Risks of Low Birthweight in Babies 

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive